Core Viewpoint - The company has entered into an agreement to acquire a 49% stake in Optimed Holding GmbH for approximately €18.375 million, marking a significant step in its global expansion strategy [1]. Group 1: Acquisition Details - The acquisition agreement allows the company to purchase 49% of Optimed Holding GmbH, with an option to acquire the remaining shares from other shareholders [1]. - Post-acquisition, Optimed will not become a subsidiary, and its financial performance will not be consolidated into the company's financial statements [1]. Group 2: Strategic Benefits - The acquisition represents a key milestone in the company's long-term commitment to global expansion, enhancing its competitive position and influence in international markets [1]. - Integration with Optimed's sales network will accelerate the global application of innovative vascular solutions, leveraging strong relationships with European medical experts [2]. - The transaction is expected to create significant manufacturing and operational synergies between Germany and China, improving product quality and operational efficiency [2]. - The company aims to fully leverage its R&D capabilities through an integrated global commercialization platform, providing advanced medical solutions to patients and healthcare professionals worldwide [2]. Group 3: Operational Integration - Following the acquisition, the company and Optimed will integrate their commercialization platforms, including sales and marketing networks, enhancing international sales capabilities [3]. - Optimed will serve as the exclusive distributor for all vascular products in markets outside of mainland China [3]. - Rüdiger Hausherr will continue as CEO of Optimed, reporting to the company's Chairman and CEO, Dr. Zhao Zhong, which will further accelerate the company's global expansion efforts [3].
归创通桥(02190)拟1837.5万欧元收购Optimed Holding 49%股权 为进...